Intangible Assets

BHC’s brands and product franchises in branded pharmaceuticals and consumer health can support some pricing power, but peers with larger innovation pipelines and stronger consumer trust generally have more durable intangible assets.

Regulatory approvals and product-specific know-how create barriers for individual assets, yet these protections are narrower than the broad patent estates and platform depth seen at stronger peers.

The company’s portfolio is more exposed to patent expiry, litigation, and commoditization than peers with newer branded assets, which limits long-run margin durability.

Intangible value is real but fragmented across multiple businesses, so it is less defensible than the concentrated IP positions of top-tier pharma peers.

Switching Costs

BHC’s customers and channel partners can often substitute competing therapies, OTC products, or service providers with limited structural friction, which keeps retention weaker than peers with embedded workflows or device ecosystems.

In pharmaceuticals and consumer health, prescribing and purchasing decisions are influenced more by efficacy, reimbursement, and price than by high switching costs, so customer lock-in is limited.

Any switching friction is usually product-specific rather than enterprise-wide, which makes the moat less durable than peers with integrated hospital, payer, or software relationships.

The company does not appear to have peer-leading contractual or technical lock-in that would materially protect pricing power over 5–10 years.

Network Effects

BHC does not operate a platform where each additional user materially increases value for other users, so network effects are not a meaningful moat driver.

Its businesses are sold through traditional healthcare and consumer channels, which do not create the self-reinforcing adoption loops seen in software or marketplace peers.

Any scale benefits from brand awareness or distribution do not compound into a true network effect, leaving the company behind peers with ecosystem-driven retention.

Because customers can choose alternatives without losing access to a broader user network, network effects do not support durable peer outperformance.

Cost Advantage

BHC can benefit from manufacturing, procurement, and distribution scale in selected categories, but peers with larger volumes and cleaner balance sheets often enjoy stronger unit-cost leverage.

The company’s cost structure has been pressured by restructuring and portfolio complexity, which weakens the consistency of any cost advantage versus more focused peers.

Some legacy assets may still produce attractive economics, but those advantages are not broad enough to guarantee sustained margin superiority across the portfolio.

Relative to peers, BHC’s cost position looks partial and asset-dependent rather than a durable all-company advantage.

Efficient Scale

Certain specialty pharmaceutical and branded consumer niches can support efficient scale, but the markets are not so concentrated that BHC can reliably deter entry the way a dominant utility or infrastructure platform can.

Peers with stronger patent exclusivity, deeper R&D pipelines, or more entrenched distribution relationships are better positioned to defend niche economics.

BHC’s scale can help spread fixed costs, yet the benefit is diluted by portfolio breadth and competitive overlap across multiple end markets.

Efficient scale exists in pockets, but it is not strong enough to make competitors materially dependent on BHC for core industry functioning.

Overall Score

BHC shows some moat support from product-specific intangibles and selective scale benefits, but the absence of meaningful switching costs, network effects, or industry-level efficient scale leaves its competitive advantage weaker and less durable than stronger healthcare peers.